MilliporeSigma Awarded its First CRISPR Patent by Australian Patent Office Posted

MilliporeSigma has announced that the Australian Patent Office has granted the company patent rights relating to the use of CRISPR in a genomic integration method for eukaryotic cells.

The patent is the first that MilliporeSigma, a leader in genome editing, has received for CRISPR technology. The patent covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR.

"MilliporeSigma has developed an incredible tool to give scientists the ability to find new treatments and cures for conditions for which there are limited options, including cancer, rare diseases and chronic conditions, such as diabetes," said Udit Batra, CEO, MilliporeSigma. "This patent decision recognizes our expertise in CRISPR technology—a body of knowledge that we are committed to grow."

MilliporeSigma has patent filings for its insertion CRISPR method in Brazil, Canada, China, Europe, India, Israel, Japan, Singapore, South Korea, and the U.S.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging—from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

MilliporeSigma has a 14-year history in the genome-editing field. It was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

With MilliporeSigma's CRISPR genomic integration technology, scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creation of disease models and gene therapy. Additionally, scientists can use the method to insert transgenes that label endogenous proteins for visual tracking within cells.

In May 2017, MilliporeSigma announced that it had developed an alternative CRISPR genome-editing method called proxy-CRISPR. Unlike other systems, MilliporeSigma's proxy-CRISPR technique can cut previously unreachable cell locations, making CRISPR more efficient, flexible and specific, and giving researchers more experimental options. MilliporeSigma has filed several patent applications on its proxy-CRISPR technology, and those applications are just the latest of multiple CRISPR patent filings made by the company since 2012.

In addition to basic gene-editing research, MilliporeSigma supports development of gene- and cell-based therapeutics and manufactures viral vectors. In 2016, MilliporeSigma launched a genome-editing initiative aimed at advancing research in novel modalities—from genome editing to gene medicine manufacturing—through a dedicated team and enhanced resources, further solidifying the company's commitment to the field.